Miller, KL, Fermaglich, LJ, Maynard, J. Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases. Orphanet J Rare Dis. 2021;16 (1):265. doi: 10.1186/s13023-021-01901-6. PubMed PMID:34107994 PubMed Central PMC8191002.
Zhang, L, Wang, J. Incentives to promote the US pharmaceutical innovation: empirical research based on the case of Epogen. Drug Dev Ind Pharm. 2021; :1-5. doi: 10.1080/03639045.2021.1935997. PubMed PMID:34056986 .
Park, K, Virparia, R, Green, DJ, Epps, C, Wharton, GT, McCune, SK et al.. Inclusion of Infants and Neonates in Pediatric Orphan Product Approvals. Clin Pharmacol Ther. 2021; :. doi: 10.1002/cpt.2306. PubMed PMID:34028811 .
Pani, L, Becker, K. New Models for the Evaluation of Specialized Medicinal Products: Beyond Conventional Health Technology Assessment and Pricing. Clin Drug Investig. 2021;41 (6):529-537. doi: 10.1007/s40261-021-01041-6. PubMed PMID:34014509 .
Schmidt, L, Sehic, O, Wild, C. EU FP7 research funding for an orphan drug (Orfadin®) and vaccine (Hep C) development: a success and a failure?. J Pharm Policy Pract. 2021;14 (1):37. doi: 10.1186/s40545-021-00317-8. PubMed PMID:33910624 PubMed Central PMC8080091.
Raghu, VK, Mezoff, EA, Cole, CR, Rudolph, JA, Smith, KJ. Cost-effectiveness of ethanol lock prophylaxis to prevent central line-associated bloodstream infections in children with intestinal failure in the United States. JPEN J Parenter Enteral Nutr. 2021; :. doi: 10.1002/jpen.2130. PubMed PMID:33908050 .
de Andrés-Nogales, F, Cruz, E, Calleja, MÁ, Delgado, O, Gorgas, MQ, Espín, J et al.. A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study). Orphanet J Rare Dis. 2021;16 (1):186. doi: 10.1186/s13023-021-01809-1. PubMed PMID:33902672 PubMed Central PMC8073956.
Li, X, Zhang, X, Zhang, S, Lu, Z, Zhang, J, Zhou, J et al.. Rare disease awareness and perspectives of physicians in China: a questionnaire-based study. Orphanet J Rare Dis. 2021;16 (1):171. doi: 10.1186/s13023-021-01788-3. PubMed PMID:33849615 PubMed Central PMC8042908.
Hagendijk, ME, van der Schans, S, Boersma, C, Postma, MJ, van der Pol, S. Economic evaluation of orphan drug Lutetium-Octreotate vs. Octreotide long-acting release for patients with an advanced midgut neuroendocrine tumour in the Netherlands. Eur J Health Econ. 2021; :. doi: 10.1007/s10198-021-01303-2. PubMed PMID:33829344 .
Liu, I, Colmenares, E, Tak, C, Vest, MH, Clark, H, Oertel, M et al.. Development and validation of a predictive model to predict and manage drug shortages. Am J Health Syst Pharm. 2021; :. doi: 10.1093/ajhp/zxab152. PubMed PMID:33821926 .
Johannesen, S, Huie, JR, Budeus, B, Peters, S, Wirth, AM, Iberl, S et al.. Modeling and Bioinformatics Identify Responders to G-CSF in Patients With Amyotrophic Lateral Sclerosis. Front Neurol. 2021;12 :616289. doi: 10.3389/fneur.2021.616289. PubMed PMID:33815246 PubMed Central PMC8012841.
Tomeo, F, Mariz, S, Brunetta, AL, Stoyanova-Beninska, V, Penttila, K, Magrelli, A et al.. Haemophilia, state of the art and new therapeutic opportunities, a regulatory perspective. Br J Clin Pharmacol. 2021; :. doi: 10.1111/bcp.14838. PubMed PMID:33772837 .
Lochmüller, H, Ramirez, AN, Kakkis, E. Disease monitoring programs of rare genetic diseases: transparent data sharing between academic and commercial stakeholders. Orphanet J Rare Dis. 2021;16 (1):141. doi: 10.1186/s13023-021-01687-7. PubMed PMID:33743771 PubMed Central PMC7980582.
Lebecque, P, Thimmesch, M. [Cystic fibrosis prognosis in Europa : chronicle of an announced dilemma]. Rev Med Liege. 2021;76 (3):202-207. . PubMed PMID:33682390 .
Peddapalli, A, Gehani, M, Kalle, AM, Peddapalli, SR, Peter, AE, Sharad, S et al.. Demystifying Excess Immune Response in COVID-19 to Reposition an Orphan Drug for Down-Regulation of NF-κB: A Systematic Review. Viruses. 2021;13 (3):. doi: 10.3390/v13030378. PubMed PMID:33673529 PubMed Central PMC7997247.
Gennet, É. Introducing 'Health Vulnerability'. Towards a Human Right Claim for Innovative Orphan Drugs?. Eur J Health Law. 2020;27 (3):290-307. doi: 10.1163/15718093-BJA10005. PubMed PMID:33652405 .
Chua, KP, Kimmel, LE, Conti, RM. Spending For Orphan Indications Among Top-Selling Orphan Drugs Approved To Treat Common Diseases. Health Aff (Millwood). 2021;40 (3):453-460. doi: 10.1377/hlthaff.2020.01442. PubMed PMID:33646878 PubMed Central PMC8011952.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.